According to a press release from Tryton Medical, the first patient has been enrolled in the post approval study to evaluate the Tryton side-branch stent for the treatment of coronary artery disease. R Jobe—partner of Joel Schneider (the principal investigator of the study)—performed the first case at NC Heart and Vascular in Raleigh (USA).
The Tryton side-branch stent system was built using proprietary Tri-ZONE technology and is designed to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side-branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The Tryton side-branch stent has now been used to treat more than 12,000 patients worldwide. It is commercially available in multiple countries within Europe, the Middle East and Africa, and is approved for use in the USA.
Schneider says: “The Tryton stent has become the preferred strategy for predictably treating my patients with coronary bifurcation lesions. This post-approval study is anticipated to confirm the excellent procedural and long term clinical outcomes we obtained in the Tryton pivotal study.”
“Greater than 20% of all percutaneous coronary interventions involve a bifurcation for which Tryton is the only FDA approved device. The enrolment of the first patient in the study is yet another milestone for Tryton, confirming the company’s commitment to education and understanding of the treatment of bifurcation disease in complex PCI,” comments Carl St. Bernard, president and CEO of Tryton Medical.
